BioTime Inc (BTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
90
About the Report
About the Report
Summary
BioTime Inc (BioTime) is a clinical-stage biotechnology company. It focuses on developing cures or treatments based on its core proprietary technology platforms for cell replacement and cell/drug delivery.The company's aesthetics products under development include Renevia , a potential treatment for facial lipoatrophy and facial aesthetics; Premvia for tendon and wound-management applications; OpRegen for the treatment of dry form of age-related macular degeneration (AMD); product for retinal restoration; HyStem for stroke recovery; ReGlyde for viscosupplementation and drug delivery; and bone grafting products. BioTime's products can be used in oncology, neuroscience, orthopedics and blood and vascular diseases. It also has interests in companies involved in offering therapeutic products in oncology and neurology, and biopsy tests for diagnosis of cancer. The company has operations in the US, Hong Kong, Israel and Singapore. BioTime is headquartered in California, the US.
BioTime Inc (BTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
BioTime Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
BioTime Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
BioTime Inc, Medical Devices Deals, 2012 to YTD 2018 11
BioTime Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
BioTime Inc, Pharmaceuticals & Healthcare, Deal Details 15
Asset Purchase 15
AgeX Therapeutics Acquires Patents and Patent Applications from Escape Therapeutics 15
BioTime Completes Acquisition Of Stem Cell Assets From Geron 16
Venture Financing 18
AgeX Therapeutics Raises USD0.5 Million in Venture Financing 18
AgeX Therapeutics Raises USD8.9 Million in Venture Financing 19
Partnerships 20
BioTime and Hepregen Form Joint Venture 20
Licensing Agreements 21
Processa Pharma Enters into Licensing Agreement with BioTime 21
BioTime Enters into Licensing Agreement with Hadassah Medical 22
BioTime Enters into Licensing Agreement with University of Pittsburgh Medical Center 23
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 24
BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 25
Asterias Biotherapeutics Enters into Licensing Agreement with BioTime and ES Cell International 26
BioTime Enters into Licensing Agreement with Asterias Biotherapeutics 27
ES Cell International Enters into Licensing Agreement with Beckman Research Institute 28
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 29
BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 30
Equity Offering 31
BioTime Completes Public Offering of Shares for USD28.8 Million 31
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 33
BioTime to Raise up to USD25 Million in Private Placement of Shares 35
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 36
BioTime Raises USD20 Million in Public Offering of Shares 37
OncoCyte Raises USD3.2 Million in Private Placement of Units 39
OncoCyte Raises USD7.3 Million in Private Placement of Units 40
BioTime Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD20 Million 41
BioTime Raises USD5 Million in Private Placement of Shares 43
BioTime Raises USD20.4 Million in Private Placement of Shares 44
BioTime Raises USD8.6 Million in Private Placement of Shares 46
BioTime Raises USD29 Million in Private Placement of Shares 47
BioTime Completes Private Placement Of Shares For USD 6.4 Million 49
BioTime Announces Public Offering Of Shares For Up To USD 15 Million 50
BioTime Completes Public Offering Of Shares For USD 3.5 Million 51
BioTime Completes Private Placement Of Units For USD 9 Million 52
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For USD 3 Million 53
BioTime Announces Private Placement Of Common Stock 55
Acquisition 56
BioIVT Acquires Ascendance Biotech 56
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 57
BioTime And LifeMap Sciences Acquire XenneX, Biomedical Research Services Company 59
BioTime Inc-Key Competitors 60
BioTime Inc-Key Employees 61
BioTime Inc-Locations And Subsidiaries 62
Head Office 62
Other Locations & Subsidiaries 62
Joint Venture 63
Recent Developments 64
Strategy And Business Planning 64
Apr 06, 2017: BioTime Forms New Subsidiary AgeX Therapeutics to Develop its Programs Focused on Human Aging 64
Financial Announcements 65
Aug 02, 2018: BioTime reports second quarter results and recent corporate accomplishments-2018 65
May 10, 2018: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 67
Mar 15, 2018: BioTime Reports Fourth Quarter and Fiscal 2017 Results 69
Nov 09, 2017: BioTime Reports Third Quarter Results and Recent Corporate Accomplishments 71
Aug 02, 2017: BioTime Reports Second Quarter Results and Recent Accomplishments 73
May 10, 2017: BioTime Reports First Quarter Results and Recent Corporate Accomplishments 75
Mar 16, 2017: BioTime Reports Fourth Quarter and Fiscal Year 2016 Financial Results and Recent Corporate Accomplishments 77
Corporate Communications 80
Sep 18, 2018: BioTime appoints Brian Culley as chief executive officer 80
Jun 05, 2018: AgeX Therapeutics Appoints John F. Mauldin to Board of Directors 82
Feb 22, 2018: BioTime Names Cavan Redmond As Board Director 83
Government and Public Interest 84
Jun 29, 2018: BioTime Awarded Grant from the National Institutes of Health 84
Jun 29, 2018: BioTime Awarded Grant From the NIH (National Institutes of Health) 85
May 02, 2018: AgeX Announces NIH Grant Award 86
Sep 18, 2017: BioTime Awarded Grant from the NIH 87
Product News 88
Jan 02, 2018: AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer 88
Other Significant Developments 89
Jun 19, 2017: Biotime Expands & Advances Ophthalmology Portfolio 89
Appendix 90
Methodology 90
About GlobalData 90
Contact Us 90
Disclaimer 90
List of Figure
List of Figures
BioTime Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
BioTime Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
BioTime Inc, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
BioTime Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
BioTime Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
BioTime Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
BioTime Inc, Deals By Therapy Area, 2012 to YTD 2018 10
BioTime Inc, Medical Devices Deals, 2012 to YTD 2018 11
BioTime Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
AgeX Therapeutics Acquires Patents and Patent Applications from Escape Therapeutics 15
BioTime Completes Acquisition Of Stem Cell Assets From Geron 16
AgeX Therapeutics Raises USD0.5 Million in Venture Financing 18
AgeX Therapeutics Raises USD8.9 Million in Venture Financing 19
BioTime and Hepregen Form Joint Venture 20
Processa Pharma Enters into Licensing Agreement with BioTime 21
BioTime Enters into Licensing Agreement with Hadassah Medical 22
BioTime Enters into Licensing Agreement with University of Pittsburgh Medical Center 23
Heraeus Medical Enters into Licensing Agreement with OrthoCyte 24
BioTime Extends Licensing Agreement With Jade Therapeutics For HyStem Technology 25
Asterias Biotherapeutics Enters into Licensing Agreement with BioTime and ES Cell International 26
BioTime Enters into Licensing Agreement with Asterias Biotherapeutics 27
ES Cell International Enters into Licensing Agreement with Beckman Research Institute 28
BioTime Enters Into Licensing Agreement With University of California, Los Angeles 29
BioTime Enters Into Licensing Agreement With Wistar Institute For SP100 30
BioTime Completes Public Offering of Shares for USD28.8 Million 31
Biotime Plans to Raise up to USD15 Million in Public Offering of Shares 33
BioTime to Raise up to USD25 Million in Private Placement of Shares 35
OncoCyte Raises USD2 Million in Private Placement of Shares upon Exercise of Warrants 36
BioTime Raises USD20 Million in Public Offering of Shares 37
OncoCyte Raises USD3.2 Million in Private Placement of Units 39
OncoCyte Raises USD7.3 Million in Private Placement of Units 40
BioTime Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares for USD20 Million 41
BioTime Raises USD5 Million in Private Placement of Shares 43
BioTime Raises USD20.4 Million in Private Placement of Shares 44
BioTime Raises USD8.6 Million in Private Placement of Shares 46
BioTime Raises USD29 Million in Private Placement of Shares 47
BioTime Completes Private Placement Of Shares For USD 6.4 Million 49
BioTime Announces Public Offering Of Shares For Up To USD 15 Million 50
BioTime Completes Public Offering Of Shares For USD 3.5 Million 51
BioTime Completes Private Placement Of Units For USD 9 Million 52
BioTime Accelerates Closing Date For Second Tranche Of Private Placement Of Shares For USD 3 Million 53
BioTime Announces Private Placement Of Common Stock 55
BioIVT Acquires Ascendance Biotech 56
BioTime Acquires 62.6% Stake in Cell Cure Neurosciences for USD3.5 Million 57
BioTime And LifeMap Sciences Acquire XenneX, Biomedical Research Services Company 59
BioTime Inc, Key Competitors 60
BioTime Inc, Key Employees 61
BioTime Inc, Subsidiaries 62
BioTime Inc, Joint Venture 63
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.